Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance

Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.